Literature DB >> 31547081

Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections.

Leroy Versteeg1,2,3, Mashal M Almutairi4,5,6, Peter J Hotez7,8,9,10, Jeroen Pollet11,12.   

Abstract

Despite medical progress, more than a billion people still suffer daily from parasitic infections. Vaccination is recognized as one of the most sustainable options to control parasitic diseases. However, the development of protective and therapeutic vaccines against tropical parasites has proven to be exceptionally challenging for both scientific and economic reasons. For certain parasitic diseases, traditional vaccine platforms are not well-suited, due to the complexity of the parasite life cycles and the parasite's ability to evade the human immune system. An effective anti-parasite vaccine platform needs to have the ability to develop and test novel candidate antigens fast and at high-throughput; it further needs to allow for multivalent combinations and must evoke a strong and well-defined immune response. Anti-parasitic vaccines need to be safe and economically attractive, especially in the world's low- and middle-income countries. This review evaluates the potential of in vitro transcribed mRNA vaccines as a new class of preventive and therapeutic vaccine technologies for parasitic infections.

Entities:  

Keywords:  CD8+ T cells; messenger RNA; multivalent vaccines; neglected tropical diseases

Year:  2019        PMID: 31547081     DOI: 10.3390/vaccines7040122

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  16 in total

1.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

2.  A historical and systematic overview of Ascaris vaccine development.

Authors:  Ana Clara Gazzinelli-Guimarães; Pedro Gazzinelli-Guimarães; Jill E Weatherhead
Journal:  Parasitology       Date:  2021-08-09       Impact factor: 3.243

Review 3.  mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Authors:  Shugang Qin; Xiaoshan Tang; Yuting Chen; Kepan Chen; Na Fan; Wen Xiao; Qian Zheng; Guohong Li; Yuqing Teng; Min Wu; Xiangrong Song
Journal:  Signal Transduct Target Ther       Date:  2022-05-21

Review 4.  Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids.

Authors:  Gyan Prakash; Ahmed Shokr; Niels Willemen; Showkeen Muzamil Bashir; Su Ryon Shin; Shabir Hassan
Journal:  Adv Drug Deliv Rev       Date:  2022-03-12       Impact factor: 17.873

Review 5.  Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens.

Authors:  Cristina Poveda; Amadeo B Biter; Maria Elena Bottazzi; Ulrich Strych
Journal:  Vaccines (Basel)       Date:  2019-09-27

Review 6.  The 2020 race towards SARS-CoV-2 specific vaccines.

Authors:  Tomasz M Karpiński; Marcin Ożarowski; Agnieszka Seremak-Mrozikiewicz; Hubert Wolski; Donald Wlodkowic
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

7.  The Race for a COVID-19 Vaccine: Current Trials, Novel Technologies, and Future Directions.

Authors:  Stav Brown; Tal Brown; Paul S Cederna; Rod J Rohrich
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-09-28

Review 8.  Paving the Road for RNA Therapeutics.

Authors:  Niels Dammes; Dan Peer
Journal:  Trends Pharmacol Sci       Date:  2020-09-03       Impact factor: 14.819

Review 9.  Application of Dendrimers for Treating Parasitic Diseases.

Authors:  Veronica Folliero; Carla Zannella; Annalisa Chianese; Debora Stelitano; Annalisa Ambrosino; Anna De Filippis; Marilena Galdiero; Gianluigi Franci; Massimiliano Galdiero
Journal:  Pharmaceutics       Date:  2021-03-05       Impact factor: 6.321

Review 10.  mRNA, a Revolution in Biomedicine.

Authors:  Bruno Baptista; Rita Carapito; Nabila Laroui; Chantal Pichon; Fani Sousa
Journal:  Pharmaceutics       Date:  2021-12-05       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.